United KingdomResearchers have developed a method to deliver therapeutic antibodies into cells using lipid nanoparticles. This technique involves modifying the surface of antibodies with a negatively charged ion, allowing them to bind to positively charged lipid nanoparticles. These nanoparticles act as carriers, transporting the antibodies across cell membranes to reach intracellular targets. The method has been tested in inhibiting cancer cells, lung inflammation, and Parkinson's disease. The technology was initially developed by researchers at Cornell University and later successfully applied by a team at the Technion-Israel Institute of Technology to deliver anti-alpha-synuclein antibodies for Parkinson's disease treatment.
Bias read (Center): The article discusses scientific research focused on medical advancements and does not involve political figures, policies, or contentious issues. It presents findings from academic institutions and focuses on technological innovation rather than any politically charged subject matter.
